Form 4: Trevi Therapeutics CFO Lisa Delfini Reports Stock Transactions

Lisa Delfini, CFO of Trevi Therapeutics, reports the acquisition and disposal of common stock and stock options on May 22, 2024, including shares sold to cover tax obligations.

Summary

• Lisa Delfini, the Chief Financial Officer of Trevi Therapeutics, reported transactions involving the company's common stock and stock options on May 22, 2024.
• Delfini acquired 16,043 shares of common stock through the exercise of stock options at a price of $0.511 per share.
• Simultaneously, she sold 4,350 shares at a weighted average price of $2.6402 per share, with prices ranging from $2.64 to $2.65, to cover tax withholding obligations related to the option exercise.
• Following these transactions, Delfini directly owns 53,279 shares of Trevi Therapeutics common stock, which includes 5,685 shares purchased through the company's employee stock purchase plan.
• She also holds options to purchase 48,125 shares of common stock.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The CFO's exercise of stock options could be seen as a positive signal, indicating confidence in the company's future performance.

Negatives

• The sale of shares to cover tax obligations, while routine, could be perceived negatively if investors interpret it as a lack of confidence, although it is a standard practice.

Risks

• There are no specific risks mentioned in this document.
• However, insider transactions are always subject to scrutiny and potential misinterpretation by the market.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly listed companies like Trevi Therapeutics.
• Comparable companies in the pharmaceutical or biotech sector, such as Amgen (AMGN) or Biogen (BIIB), also regularly report Form 4 filings by their executives and directors.
• The specifics of the transactions (exercise price, sale price, number of shares) are unique to Trevi Therapeutics and its executive compensation plans.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as insider transactions are often scrutinized for signals about the company's health.
• The impact on employees, customers, suppliers, and creditors is likely negligible.

Key Dates